The CPACS 1a/1b is open label so results are available once first patient data is known although it may be in batches or as the company deems appropriate (unless adverse which should not be withheld). So if it starts later this year we may be lucky with readouts if trial approval and recruitment goes well, but more likely in 2025 for expectations and H1 would be good.
CPACS: Research, Results, Market Comparisons, and Valuations, page-75
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.015(0.89%) |
Mkt cap ! $289.6M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.70 | $1.69 | $46.27K | 27.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 121 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.71 | 1500 | 1 |
View Market Depth
| Last trade - 11.03am 16/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |